NetScientific PLC Glycotest Inc. appoints medical advisory board (9237K)
06 Janeiro 2016 - 5:00AM
UK Regulatory
TIDMNSCI
RNS Number : 9237K
NetScientific PLC
06 January 2016
NetScientific plc
NetScientific portfolio company, Glycotest Inc., appoints world
leading medical advisory board chaired by David Chernoff, M.D.
London, UK - 6 January 2016 - NetScientific plc ("NetScientific"
or the "Group", AIM: NSCI), the transatlantic biomedical and
healthcare technology group, appoints a medical advisory board of
leading liver experts to advise on the development of Glycotest's
diagnostic tests for liver related diseases.
Scott Friedman, MD and Douglas Dieterich, MD have been appointed
to the advisory board alongside the chair, David Chernoff, MD.
Glycotest is a molecular diagnostics company commercialising
clinical laboratory testing services to reduce mortality and
increase survival for patients at risk from liver cancers and
fibrosis-cirrhosis. Glycotest employs unique non-invasive blood
tests based on proprietary serum biomarkers, biomarker panels and
assay methodology that exploit novel sugar-based disease signal
chemistry.
David Chernoff, MD is a molecular diagnostics industry veteran
who has played pivotal roles in the launch of multiple products
such Vectra DA (Crescendo Bioscience), AlloMap (CareDx) and HIV,
HBV and HCV bDNA tests (Chiron Diagnostics). He brings both senior
clinical leadership experience and a key commercial perspective to
his role as chair of Glycotest's Medical Advisory Board. Dr.
Chernoff has served as Chief Medical Officer at multiple
entrepreneurial molecular diagnostics companies, most recently
Crescendo Bioscience, and previously was Vice President of
Corporate Technology at Elan Pharmaceuticals and Medical Director
at Chiron Diagnostics. Dr. Chernoff holds an MD degree from New
York University and completed his medical training at the
University of California, San Francisco.
Scott Friedman, MD is Chief of the Division of Liver Diseases
and Dean for Therapeutic Discovery at the Icahn School of Medicine
at Mount Sinai, New York and was President of the American
Association for the Study of Liver Diseases (AASLD) in 2009. Dr.
Friedman is one of the foremost leaders in the field of liver
fibrosis, having been the first to isolate and characterise the
causative cell type. He contributes a wealth of experience with
emerging diagnostic and therapeutic approaches in serious liver
disease. Dr. Friedman received his MD degree from Mount Sinai and
completed his training at Beth Israel Hospital, Boston and the
University of California, San Francisco.
Douglas Dieterich, MD is Professor of Medicine at the Icahn
School of Medicine at Mount Sinai, New York with appointments in
the Divisions of Liver Diseases, Gastroenterology and Infectious
Diseases, and is the newly appointed Director for the Institute for
Liver Medicine at the Mount Sinai Health System. Chronic hepatitis
B and C are key focal areas of Dr. Dieterich's clinical research
and he has authored many publications on viral hepatitis and
AIDS-related infections of the liver. His extensive clinical
practice experience in serious liver disease will be a vital
resource for Glycotest. Dr. Dieterich's MD degree is from New York
University School of Medicine and he completed his medical training
at Bellevue Hospital Center in New York.
Commenting on the appointments, NetScientific's Chief Executive
Officer, Francois R. Martelet said: "Dr. Chernoff's appointment as
Chairman of Glycotest's Medical Advisory Board and the appointments
of Dr Scott Friedman and Dr Douglas Dieterich complements our
strategy of advancing the development and commercialisation of
these novel tests in the US market. We look forward to drawing upon
the team's extensive experience within the specific liver disease
market that we are initially focusing on."
- Ends -
Contact Details
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet, M.D.,
CEO
Peter Thoms, CFO
Tel: +44 (0)20 7597 4000
Investec (NOMAD and broker)
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7457 2020
Instinctif Partners Email: netscientific@instinctif.com
Melanie Toyne-Sewell / Jayne Crook
/ Rosanna Forrest
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
About Glycotest
Glycotest is a molecular diagnostics company commercialising
novel clinical laboratory testing services for patients at risk for
liver cancers and fibrosis-cirrhosis. The Company was founded in
2012 on proprietary technology that originated at the Philadelphia
area institutions Baruch S. Blumberg Institute and Drexel
University College of Medicine. Glycotest provides financial
compensation to the members of the Medical Advisory Board for their
service. www.glycotest.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSMFMIFMSEFF
(END) Dow Jones Newswires
January 06, 2016 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024